Drug Profile
Neural cell replacement therapy - Ophiuchus Technologies
Alternative Names: Autologous neural stem cell therapy - Ophiuchus Technologies; Autologous neural stem cells - Ophiuchus Technologies; Directly reprogrammed neural stem cells - Ophiuchus Technologies; DrSC™ NeuralLatest Information Update: 24 Jul 2023
Price :
$50
*
At a glance
- Originator Ophiuchus Technologies
- Developer Federal Medical and Biological Agency of Russia; Ophiuchus Technologies
- Class Neural stem cell therapies; Neuroprotectants
- Mechanism of Action Cell replacements; Neurogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Brain injuries; Spinal cord injuries
Most Recent Events
- 24 Jul 2023 Discontinued - Phase-I/II for Spinal cord injuries in Russia (Intraspinal)
- 24 Jul 2023 Discontinued - Phase-I/II for Spinal cord injuries in Russia (Intrathecal)
- 24 Jul 2023 Discontinued - Preclinical for Brain injuries in Switzerland (Parenteral)